🔬 Current Disease Focus:
Task Progress: 0%
👥 Active Problem Solvers
0
🌍 Experts collaborating globally
⚡ Current Task Assignment
🧬 Genetic Analysis
🔄 Matching experts to specific tasks
📊 Resource Allocation by Research Phase:
📚 Data Analysis
🧪 Experimental Design
🔬 Clinical Trials
💊 Treatment Development
This is a phase 1b/2 study of KRT-232 combined with ruxolitinib in subjects...
Status
Unknown
Location
City of Hope
Start Date
2021-01-28
Trial ID
NCT04485260
Treatments Being Tested
This clinical trial is evaluating whether addition of navtemadlin to ruxoli...
Status
Recruiting
Location
UAB Hospital
Start Date
2024-06-03
Trial ID
NCT06479135
Treatments Being Tested
This phase Ib trial studies the side effects and best dose of navtemadlin w...
Status
Active Not Recruiting
Location
Los Angeles General Medical Center
Start Date
2021-02-04
Trial ID
NCT04190550
Treatments Being Tested
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2...
Status
Terminated
Location
University of Chicago
Start Date
2019-09-25
Trial ID
NCT04113616
Treatments Being Tested
This phase Ib trial studies the side effects of navtemadlin and radiation t...
Status
Completed
Location
CTCA at Western Regional Medical Center
Start Date
2018-06-20
Trial ID
NCT03217266
Treatments Being Tested
This study evaluates TL-895, a potent, orally available and highly selectiv...
Status
Unknown
Location
Keck School of Medicine
Start Date
2021-03-31
Trial ID
NCT04669067
This study evaluates KRT-232 in Combination With TL-895 for the Treatment o...
Status
Unknown
Location
University of Alabama at Birmingham School of Medicine, Division of Hematology and Oncology
Start Date
2020-11-17
Trial ID
NCT04640532
This phase I trial studies the side effects and best dose of MDM2 Inhibitor...
Status
Terminated
Location
University of California Davis Comprehensive Cancer Center
Start Date
2018-06-14
Trial ID
NCT03031730
This phase I trial studies the side effects and best dose of navtemadlin in...
Status
Terminated
Location
University of Alabama at Birmingham Cancer Center
Start Date
2018-07-09
Trial ID
NCT03107780
Treatments Being Tested